We are excited that as of today our functional mushroom nutraceutical product, GOODMIND™ is available online. The GOODMIND™ formulas harness the power of adaptogens, these are non-toxic, non-psychoactive fungi, used for centuries in traditional medicine for their stress-relieving benefits. GOODMIND™ is designed to nourish the mind and elevate everyday life by enhancing mental capacity and the body’s ability to adapt to stress.
Psyence has signed a partnership agreement with Clerkenwell Health, a leading psychedelic Contract Research Organisation (CRO) based in the United Kingdom to develop market leading clinical trials in the field of palliative care. Clerkenwell will be responsible for jointly designing and delivering the UK clinical trial. Palliative care is the treatment and alleviation of suffering for those facing a serious acute or persistent medical issue, whether the prognosis is deemed terminal or chronic and ongoing.
Today Dr. Neil Maresky joins Psyence as Chief Executive Officer. Dr. Maresky brings more than 20 years of biopharmaceutical expertise to our team; he will oversee strategy and operations of Psyence, and will be based in Canada. Dr. Maresky has been instrumental in the launch, commercialization, and uptake of many ground breaking innovations, which have positively impacted the health of millions of patients across Canada.
Collaboration with the Scientific Research Council (SRC) of Jamaica for Psilocybin Product Development
Psyence Group Announces a Collaboration with the Scientific Research Council (SRC) of Jamaica for Psilocybin Product Development
Psyence establishes Psyence Jamaica as part of its strategy to develop standardized nutraceutical and pharmaceutical psychedelic products in Jamaica for the treatment of psychological traumas.
Psyence Group Inc. (CSE: PSYG) (“Psyence” or the “Company”) is pleased to provide the following corporate update on its three clear paths to revenue and value creation namely: Psyence Production, Psyence Therapeutics and Psyence Function.
Psyence Group Inc. (CSE: PSYG) (“Psyence”), and Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) (“Pure Extracts”) and are pleased to announce the signing of a Letter of Intent (“LOI”) to form a Joint Venture (the “JV”) to develop superior techniques for the extraction of psilocybin from psychedelic mushrooms, as well as the development of advanced formulations containing psilocybin for the long-term treatment of psychological trauma and its mental health consequences.